PT-141: The Brain-Based Peptide Researchers Are Studying for Sexual Health
What Exactly Is PT-141?
PT-141 is a small synthetic peptide — a short chain of amino acids built in a lab. Its scientific name is bremelanotide. Researchers designed it as a modified version of a natural hormone called alpha-MSH (alpha-melanocyte-stimulating hormone).[3]
That might sound complicated. Here's the simple version: your body has a family of receptors called melanocortin receptors. Some of them — specifically MC3R and MC4R — sit in the brain and are linked to sexual arousal and response.[3] PT-141 binds to those receptors and switches them on.
This makes PT-141 fundamentally different from drugs like sildenafil (Viagra). Sildenafil works by relaxing blood vessels. PT-141 works by talking to the brain first.[6] That's why researchers got excited about it.
How Did PT-141 Get on Scientists' Radar?
Early animal studies were striking. When PT-141 was given to rats and non-human primates, it reliably produced penile erections — and brain imaging showed activity in the hypothalamus, the region that helps control sexual behavior.[3] Those preclinical results pushed researchers toward human trials.
By the mid-2000s, the biotech company Palatin Technologies had moved PT-141 through Phase II clinical trials for erectile dysfunction (ED) and was planning Phase III studies.[1] The goal was an intranasal spray — a nasal delivery method that would get the peptide into circulation quickly.
What Do Human Studies Actually Show?
Dose-Dependent Erectile Response
In one key study, researchers gave healthy men and ED patients subcutaneous (under-the-skin) injections of PT-141 at doses ranging from 0.3 mg to 10 mg. Using a device called RigiScan — which measures erection quality objectively — they found a statistically significant erectile response at doses above 1.0 mg in healthy subjects. In ED patients, significant responses were seen at both 4 mg and 6 mg doses.[5] The compound was described as safe and well-tolerated in that study.
Helping Men Who Don't Respond to Viagra
That's an important finding. A meaningful number of men don't get adequate results from PDE5 inhibitors like sildenafil. The same subcutaneous study found that PT-141 produced significant erections in patients who reported that Viagra worked less than 50% of the time.[5] This suggested a potentially different patient population could benefit — because the mechanism of action is completely separate from PDE5 inhibition.[6]
Combining PT-141 With Sildenafil
Researchers also tested what happens when you use both together at low doses. In a crossover trial, 19 ED patients received either intranasal PT-141 (7.5 mg) plus low-dose sildenafil (25 mg), sildenafil alone, or a placebo. The combination produced a significantly greater erectile response than sildenafil alone — and importantly, it didn't introduce new safety concerns.[4] This hinted that combining a brain-acting peptide with a vessel-acting drug might let both work at lower, more tolerable doses.
What About Women?
The research on female sexual dysfunction is less mature, but PT-141 was originally investigated for both men and women.[1] The same central melanocortin pathways exist in females. The FDA-approved version, bremelanotide (Vyleesi), was eventually cleared specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women — making PT-141 one of the few compounds with a regulatory track record in female sexual health.
What Researchers Still Don't Know
The honest answer is: quite a bit. A 2025 review from the University of Miami noted that while PT-141 shows efficacy through central nervous system activation, large-scale clinical trials are still needed to fully establish safety profiles, optimal dosing regimens, and potential synergistic effects with existing treatments.[6] Most published trials are relatively small. Longer-term data is limited.
Common side effects reported in studies include nausea and flushing — dose-dependent effects that researchers are still working to minimize.[5]
There is also essentially no data on use during breastfeeding, and caution is advised in that context until more research is available.[2]
Where Does Dosage Research Stand?
The studies above used a range of doses depending on the delivery route — intranasal doses in the 7.5 mg range and subcutaneous doses from 1 mg to 10 mg in research settings.[4][5] These numbers come from specific controlled protocols and are not universal recommendations.
If you're looking for a structured reference, our PT-141 dosage chart compiles the figures used across published studies so you can see the full picture. You can also use our calculator to explore how study doses relate to body weight — a common variable in peptide research.
The Bottom Line
PT-141 is a brain-first peptide that takes a genuinely different approach to sexual health research. The evidence from human trials is promising — especially for people who haven't responded to conventional options — but it is still early-stage science. More large trials are needed before any definitive clinical conclusions can be drawn.
Sources
- PT-141 Palatin. — Current opinion in investigational drugs (London, England : 2000), 2004. PMID 15134289.
- Bremelanotide. — , 2006. PMID 31369224.
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction. — Annals of the New York Academy of Sciences, 2003. PMID 12851303.
- Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. — Urology, 2005. PMID 15833522.
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. — International journal of impotence research, 2004. PMID 14999221.
- Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. — Expert opinion on pharmacotherapy, 2025. PMID 40069591.
EN
BR
ES
FR